Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 408

The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.

Pembrolizumab in patients with thymic carcinoma: a single-arm, single-centre, phase 2 study

Open access
Giaccone, Giuseppe, Kim, Chul, Thompson, Jillian, McGuire, Colleen, Kallakury, Bhaskar, Chahine, Joeffrey J, Manning, Maria, Mogg, Robin, Blumenschein, Wendy M, Tan, Ming T, Subramaniam, Deepa S, Liu, Stephen V, Kaplan, Ian M, McCutcheon, Justine N·2018·The Lancet Oncology

Abstract

Summary Background Treatment options are limited for patients with thymic carcinoma. These aggressive tumours are not typically associated with paraneoplastic autoimmune disorders, and strong PD-L1 expression has been reported in thymic epithelial tumours. We aimed to assess the activity of pembrolizumab, a monoclonal antibody that targets PD-1, in patients with advanced thymic carcinoma. Methods We completed a single-arm phase 2 study of pembrolizumab in patients with recurrent thymic carcinoma who had progressed after at least one line of chemotherapy. This was a single-centre study performed at Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, USA. Key inclusion criteria were an Eastern Cooperative Oncology Group performance status of 0–2, no history of autoimmune disease or other malignancy requiring treatment or laboratory abnormality, and adequate organ function. Patients received 200 mg of pembrolizumab every 3 weeks for up to 2 years. The primary objective of the study was the proportion of patients who had achieved a response assessed with Response Evaluation Criteria in Solid Tumors version 1.1. Analysis was per protocol, in all eligible patients. The study is registered with ClinicalTrials.gov, number NCT02364076, and is closed to accrual; we report the final analysis. Findings 41 patients were enrolled from March 12, 2015, to Dec 16, 2016, of whom 40 were eligible and evaluable and one was excluded because of elevated liver enzymes at screening. The median follow-up was 20 months (IQR 14–26). The proportion of patients who achieved a response was 22·5% (95% CI 10·8–38·5); one (3%) patient achieved a complete response, eight (20%) patients achieved partial responses, and 21 (53%) patients achieved stable disease. The most common grade 3 or 4 adverse events were increased aspartate aminotransferase and alanine aminotransferase (five [13%] patients each). Six (15%) patients developed severe autoimmune toxicity, including two (5%) patients with myocarditis. There were 17 deaths at the time of analysis, but no deaths due to toxicity. Interpretation Pembrolizumab is a promising treatment option in patients with thymic carcinoma. Because severe autoimmune disorders are more frequent in thymic carcinoma than in other tumour types, careful monitoring is essential. Funding Merck & Co.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s1470-2045(18)30062-7

Cites

23 of 23 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 23 references

Cited by

See all 408

Metadata

Authors
Giaccone, G., Kim, C., Thompson, J., McGuire, C., Kallakury, B., Chahine, J. J., Manning, M., Mogg, R., Blumenschein, W. M., Tan, M. T., Subramaniam, D. S., Liu, S. V., Kaplan, I. M., & McCutcheon, J. N.
Venue
The Lancet Oncology
Publisher
Elsevier BV
Published
2018-03
Volume
19
Issue
3
Pages
347-355
ISSN
1470-2045 (ISSN-L)
OpenAlex
W2784751095
Cited by
408
References
23
FWCI
25.64
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Pembrolizumab in patients with thymic carcinoma: a single-arm, single-centre, phase 2 study. https://app.cochat.ai/papers/10.1016/s1470-2045(18)30062-7
The paper
Giaccone, G., Kim, C., Thompson, J., McGuire, C., Kallakury, B., Chahine, J. J., Manning, M., Mogg, R., Blumenschein, W. M., Tan, M. T., Subramaniam, D. S., Liu, S. V., Kaplan, I. M., & McCutcheon, J. N. (2018). Pembrolizumab in patients with thymic carcinoma: a single-arm, single-centre, phase 2 study. The Lancet Oncology. https://doi.org/10.1016/s1470-2045(18)30062-7

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.